scholarly journals Failure to detect infection by oral polio vaccine virus following natural exposure among inactivated polio vaccine recipients

2007 ◽  
Vol 136 (2) ◽  
pp. 180-183 ◽  
Author(s):  
H. E. GARY ◽  
B. SMITH ◽  
J. JENKS ◽  
J. RUIZ ◽  
W. SESSIONS ◽  
...  
Keyword(s):  
Oral Polio Vaccine ◽  
Developed Countries ◽  
The United States ◽  
Vaccine Virus ◽  
Susceptible Population ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine ◽  
Natural Exposure ◽  
The Us ◽  
Protection Against Infection

SUMMARYWhile oral polio vaccine (OPV) has been shown to be safe and effective, it has been observed that it can circulate within a susceptible population and revert to a virulent form. Inactivated polio vaccine (IPV) confers protection from paralytic disease, but provides limited protection against infection. It is possible, then, that an IPV-immunized population, when exposed to OPV, could sustain undetected circulation of vaccine-derived poliovirus. This study examines the possibility of polio vaccine virus circulating within the United States (highly IPV-immunized) population that borders Mexico (OPV-immunized). A total of 653 stool and 20 sewage samples collected on the US side of the border were tested for the presence of poliovirus. All samples were found to be negative. These results suggest that the risk of circulating vaccine-derived poliovirus is low in fully immunized IPV-using populations in developed countries that border OPV-using populations.

scholarly journals Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave

2022 ◽  
Vol 119 (3) ◽  
pp. e2025448119
Author(s):  
Nathaniel Hupert ◽  
Daniela Marín-Hernández ◽  
Bo Gao ◽  
Ricardo Águas ◽  
Douglas F. Nixon
Keyword(s):  
Oral Polio Vaccine ◽  
The United States ◽  
Protective Effects ◽  
Policy Makers ◽  
Polio Vaccine ◽  
Nonspecific Effects ◽  
The Us ◽  
Age Cohort ◽  
Nonpharmaceutical Interventions ◽  
Optimal Implementation

COVID-19 remains a stark health threat worldwide, in part because of minimal levels of targeted vaccination outside high-income countries and highly transmissible variants causing infection in vaccinated individuals. Decades of theoretical and experimental data suggest that nonspecific effects of non–COVID-19 vaccines may help bolster population immunological resilience to new pathogens. These routine vaccinations can stimulate heterologous cross-protective effects, which modulate nontargeted infections. For example, immunization with Bacillus Calmette–Guérin, inactivated influenza vaccine, oral polio vaccine, and other vaccines have been associated with some protection from SARS-CoV-2 infection and amelioration of COVID-19 disease. If heterologous vaccine interventions (HVIs) are to be seriously considered by policy makers as bridging or boosting interventions in pandemic settings to augment nonpharmaceutical interventions and specific vaccination efforts, evidence is needed to determine their optimal implementation. Using the COVID-19 International Modeling Consortium mathematical model, we show that logistically realistic HVIs with low (5 to 15%) effectiveness could have reduced COVID-19 cases, hospitalization, and mortality in the United States fall/winter 2020 wave. Similar to other mass drug administration campaigns (e.g., for malaria), HVI impact is highly dependent on both age targeting and intervention timing in relation to incidence, with maximal benefit accruing from implementation across the widest age cohort when the pandemic reproduction number is >1.0. Optimal HVI logistics therefore differ from optimal rollout parameters for specific COVID-19 immunizations. These results may be generalizable beyond COVID-19 and the US to indicate how even minimally effective heterologous immunization campaigns could reduce the burden of future viral pandemics.

scholarly journals Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame

2018 ◽  
Vol 67 (suppl_1) ◽  
pp. S57-S65 ◽  
Author(s):  
James T Gaensbauer ◽  
Chris Gast ◽  
Ananda S Bandyopadhyay ◽  
Miguel O’Ryan ◽  
Xavier Saez-Llorens ◽  
...  
Keyword(s):  
Oral Polio Vaccine ◽  
Polio Eradication ◽  
Maternal Antibody ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine

Letter To The Editor

PEDIATRICS ◽  
1996 ◽  
Vol 98 (4) ◽  
pp. 796-796
Author(s):  
Samuel L. Katz
Keyword(s):  
Oral Polio Vaccine ◽  
The United States ◽  
Sub Saharan Africa ◽  
Intestinal Immunity ◽  
Polio Vaccine ◽  
Polio Immunization ◽  
Individual Protection ◽  
Sub Saharan ◽  
Community Protection ◽  
Central Nervous System Invasion

Drs Terry and Schneider raise legitimate questions regarding changes in polio immunization recommendations. In response to the former, although two doses of inactivated polio vaccine provide humoral immunity that will protect an individual against central nervous system invasion by wild or revertant attenuated polioviruses, they do not provide intestinal immunity, a valued asset of oral polio vaccine (OPV). Because we live in a global community where jet transportation enables one to move from a polio-endemic area to a polio-free area in less than one day, the introduction of wild polio viruses from sub-Saharan Africa or Southeast Asia poses a legitimate threat and concern to those who wish to maintain community protection, in addition to individual protection, against possible reintroduction of wild virus to the United States.

On the Legality of the United States Action of Terminating India’s GSP Status

2020 ◽  
Vol 55 (1) ◽  
pp. 119-129
Author(s):  
R. Rajesh Babu
Keyword(s):  
Developing Countries ◽  
Dispute Settlement ◽  
Developed Countries ◽  
The United States ◽  
Appellate Body ◽  
Generalized System Of Preferences ◽  
Wto Dispute Settlement ◽  
The Us ◽  
Developmental Opportunities ◽  
Enabling Clause

Since the US Presidential Proclamation terminating India status as a Generalized System of Preferences (GSP) beneficiary with effect from 5 June 2019, questions are raised on the WTO legitimacy of such an action. The US measure, which appears to have a punitive element—a move precipitated by lack of reciprocity from India by not providing ‘equitable and reasonable access’ for US products in Indian markets—challenges the fundamentally premise of the GSP schemes. Since the GSP schemes are established to provide economic and developmental opportunities for developing countries, and once established must be administered as per the 1979 General Agreement on Tariffs and Trade Enabling Clause, meaning it must be on a ‘generalised’, ‘non-reciprocal’ and ‘non-discriminatory’ basis, can India raise a legitimate challenge against the US action at the WTO Dispute Settlement Body? Or can the GSP schemes, being voluntary and unilaterally administered, be structured by developed countries as trade policy tools with stringent trade and non-trade conditionalities? The decision of the Appellate Body in European Communities—Tariff Preferences, the contested nature of the Enabling Clause and the heterogeneous nature of developing countries at the WTO makes the interpretation knotty. In this context, this article provides a brief comment on the legal basis of the Enabling Clause in the WTO framework and the legitimacy of the US action of termination of India from the beneficiary status. Keeping aside the legal question, the author is also of the view that time is ripe for India to consider ‘graduating’ itself from such preferential arrangements and engage in binding obligations that are reciprocal and sustainable. JEL Codes: K33, O24

scholarly journals Factors associated with the utilization of inactivated polio vaccine among children aged 12 to 23 months in Kalungu District, Uganda

2020 ◽  
Vol 35 (Supplement_1) ◽  
pp. i30-i37
Author(s):  
Mirembe Rachel Faith ◽  
Babirye Juliet ◽  
Nathan Tumuhamye ◽  
Tumwebaze Mathias ◽  
Emma Sacks
Keyword(s):  
Health Care Providers ◽  
Health Workers ◽  
Oral Polio Vaccine ◽  
Systematic Sampling ◽  
Care Providers ◽  
Cross Sectional ◽  
Inactivated Polio Vaccine ◽  
Factors Associated ◽  
Polio Vaccine ◽  
Eradication Strategy

Abstract Uganda officially introduced the inactivated polio vaccine (IPV) in May 2016 as part of the polio eradication strategy and integrated it into its routine immunization programme in addition to the oral polio vaccine. The current coverage stands at 60% as of July 2017. We therefore aimed to determine factors associated with the uptake of IPV among children in Kalungu District so as to inform the implementation of the vaccine policy. A community-based cross-sectional study was conducted among caregivers of 406 eligible children aged 12–23 months through multi-stage systematic sampling and a standardized semi-structured questionnaire. Nine key informant interviews were conducted through purposive selection of health care providers and members of Village Health Teams (VHTs) based on their expertize. Modified Poisson regression and thematic content analysis were used to determine factors significant to IPV uptake among children. 71% of sampled children aged 12–23 months had received IPV in Kalungu District. The survey found that being encouraged by health workers and VHTs was significant to children’s uptake of IPV (Adjusted PR 1.24, 95% CI; 1.22–3.47). Distance to the immunization point (Adjusted PR 0.32,95% CI; 0.16–0.62) and caregiver’s education level (Adjusted PR 1.16,95% CI; 1.05–2.22) were also associated with IPV uptake. Qualitative findings from health workers and VHT members further confirmed the perception that distance to the immunization post was important, and VHTs also stated that being encouraged by health workers was critical to IPV uptake. The current prevalence of IPV uptake among children aged 12–23 months in Kalungu is 71%, higher than the last reported national coverage (60%), though still below the recommended national coverage of 95%. Efforts should be focused on sensitization of caregivers through health workers and VHTs. Immunization outreach should be strengthened so as to bring services closer to patients.

The Potential Preventive Effects of Vitamins for Cataract and Age-Related Macular Degeneration

1999 ◽  
Vol 69 (3) ◽  
pp. 198-205 ◽  
Author(s):  
Jacques
Keyword(s):  
Macular Degeneration ◽  
Developed Countries ◽  
The United States ◽  
Epidemiologic Studies ◽  
Age Related Macular Degeneration ◽  
Visual Disability ◽  
Epidemiologic Evidence ◽  
Age Related ◽  
The Us ◽  
Nutritional Antioxidants

Age-related cataract and age-related macular degeneration (AMD) are important public health problems. Approximately 50% of the 30 to 50 million cases of blindness worldwide result from unoperated cataract. In the US and other developed countries AMD is the leading cause of blindness, but age-related cataract remains the leading cause of visual disability. Age-related cataract and AMD represent an enormous economic burden. In the United States more than 1.3 million cataract extractions are performed annually at a cost of approximately $ 3.5 billion. Much of the experimental research on the etiology of cataract and AMD has focused on the role of nutritional antioxidants (vitamin C, vitamin E, and carotenoids). Evidence from epidemiologic studies support a role for nutritional antioxidants in delaying the onset of these age-related vision disorders. Although it is not yet possible to conclude that antioxidant nutrients have a role in prevention of cataract or AMD, a summary of the epidemiologic evidence suggests that it is prudent to consume diets high in vitamins C and E and carotenoids, particularly the xanthophylls, as insurance against the development of cataract and AMD.

scholarly journals Polio inactivated vaccine costs into routine childhood immunization in Brazil

2015 ◽  
Vol 49 (0) ◽  
Author(s):  
Ana Marli Christovam Sartori ◽  
Margarete Paganotti Vicentine ◽  
Lígia Castelloni Figueiredo Gryninger ◽  
Patricia Coelho de Soárez ◽  
Hillegonda Maria Dutilh Novaes
Keyword(s):  
Oral Vaccine ◽  
Oral Polio Vaccine ◽  
Inactivated Vaccine ◽  
Childhood Immunization ◽  
Immunization Program ◽  
Inactivated Polio Vaccine ◽  
Polio Vaccine ◽  
National Immunization ◽  
National Immunization Day ◽  
The Cost

OBJECTIVE To analyze the costs of vaccination regimens for introducing inactivated polio vaccine in routine immunization in Brazil.METHODS A cost analysis was conducted for vaccines in five vaccination regimens, including inactivated polio vaccine, compared with the oral polio vaccine-only regimen. The costs of the vaccines were estimated for routine use and for the “National Immunization Days”, during when the oral polio vaccine is administered to children aged less than five years, independent of their vaccine status, and the strategic stock of inactivated polio vaccine. The presented estimated costs are of 2011.RESULTS The annual costs of the oral vaccine-only program (routine and two National Immunization Days) were estimated at US$19,873,170. The incremental costs of inclusion of the inactivated vaccine depended on the number of vaccine doses, presentation of the vaccine (bottles with single dose or ten doses), and number of “National Immunization Days” carried out. The cost of the regimen adopted with two doses of inactivated vaccine followed by three doses of oral vaccine and one “National Immunization Day” was estimated at US$29,653,539. The concomitant replacement of the DTPw/Hib and HepB vaccines with the pentavalent vaccine enabled the introduction of the inactivated polio without increasing the number of injections or number of visits needed to complete the vaccination.CONCLUSIONS The introduction of the inactivated vaccine increased the annual costs of the polio vaccines by 49.2% compared with the oral vaccine-only regimen. This increase represented 1.13% of the expenditure of the National Immunization Program on the purchase of vaccines in 2011.

Sign in / Sign up

Export Citation Format

Share Document